Arbutus Biopharma

Arbutus Biopharma

Arbutus Biopharma

Arbutus (Nasdaq: ABUS) is a biopharma company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection.
Raised
$116M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$116,000,000
Post-IPO equity - 2017
Roivant Sciences
Team Size
1–10
Employees
Location
Headquarters

No recent coverage

Index constantly checks hot and trending companies for their latest activity. We haven't gotten to this company yet, but if you follow it you'll be the the first to know when Arbutus Biopharma makes some noise.